KNSA Q3 2025 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$181M+61.2% YoY

Gross Profit

$97M53.8% margin

Operating Income

$24M13.3% margin

Net Income

$18M10.2% margin

EPS (Diluted)

$0.23

QoQ Revenue Growth

+15.3%

Cash Flow

Operating Cash Flow

$34M

Free Cash Flow

$33M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$712M

Total Liabilities

$177M

Stockholders' Equity

$535M

Cash & Equivalents

$175M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$181M	$112M	+61.2%
Gross Profit	$97M	$63M	+54.9%
Operating Income	$24M	-$10M	+348.7%
Net Income	$18M	-$13M	+245.2%

Revenue Segments

Product

$181M100%